The Long and Winding Regulatory Road for Laboratory-Developed Tests

被引：25

作者：

Weiss, Ronald L. ^{[1
]}

机构：

[1] Univ Utah, Sch Med, Dept Pathol, ARUP Labs, Salt Lake City, UT 84108 USA

来源：

AMERICAN JOURNAL OF CLINICAL PATHOLOGY | 2012年 / 138卷 / 01期

关键词：

Laboratory-developed tests; In vitro diagnostic devices; Food and Drug Administration; Clinical Laboratory Improvement Amendments of 1988; Regulation; Personalized medicine;

D O I：

10.1309/AJCP6OAULC3CMFEJ

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

"High complexity" clinical laboratories are approved under the Clinical Laboratory Improvement Amendments to develop, validate, and offer a laboratory-developed test (LDT) for clinical use. The Food and Drug Administration considers LDTs to be medical devices under their regulatory jurisdiction, and that at least certain LDTs should be subject to greater regulatory scrutiny. This review describes the current regulatory framework for LDTs and suggests ways in which to appropriately enhance this framework

引用

页码：20 / 26

页数：7

共 50 条

[31] SARS-CoV-2 Laboratory-Developed Tests Integrity Restored
Adashi, Eli Y.
Cohen, I. Glenn
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 327 (13): : 1229 - 1230
[32] Laboratory-Developed Tests Account for a Small Minority of Tests Ordered in an Academic Hospital System
Rychert, Jenna
Schmidt, Robert L.
Genzen, Jonathan R.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2023, 160 (03) : 297 - 302
[33] The US FDA's proposed rule on laboratory-developed tests: Impacts on clinical laboratory testing
Smith, Leslie
Carricaburu, Lisa A.
Genzen, Jonathan R.
PRACTICAL LABORATORY MEDICINE, 2024, 40
[34] Point-Counterpoint: The FDA Has a Role in Regulation of Laboratory-Developed Tests
Caliendo, Angela M.
Hanson, Kimberly E.
JOURNAL OF CLINICAL MICROBIOLOGY, 2016, 54 (04) : 829 - 833
[35] 21st-Century Healthcare Policy and the Regulation of Laboratory-Developed Tests
Caldwell, Lexi
Terry, Sharon F.
GENETIC TESTING AND MOLECULAR BIOMARKERS, 2015, 19 (09) : 467 - 468
[36] The FDA's proposed rule on laboratory-developed tests: what happens next?
Genzen, Jonathan R.
Moser, Karen A.
LABORATORY MEDICINE, 2024, 55 (02) : 109 - 110
[37] FDA Regulation of Laboratory-Developed Diagnostic Tests Protect the Public, Advance the Science
Sharfstein, Joshua
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 313 (07): : 667 - 668
[38] Modernizing Federal Oversight of Laboratory-Developed Tests - Toward Safety, Validity, and Utility
Singhal, Udit
Horrow, Caroline
Kesselheim, Aaron S.
Morgan, Todd M.
NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (19): : 1735 - 1737
[39] POINT OF CARE TESTS: THE LONG AND WINDING ROAD TO REIMBURSEMENT
Hogue, S.
Brogan, A.
Heyes, A.
VALUE IN HEALTH, 2013, 16 (07) : A476 - A477
[40] FDA Oversight of Laboratory-Developed Tests: Is It Necessary, and How Would It Impact Clinical Laboratories?
Scott, Mitchell G.
Ashwood, Edward R.
Annesley, Thomas M.
Leonard, Debra G. B.
Burgess, Michael C.
CLINICAL CHEMISTRY, 2013, 59 (07) : 1017 - 1022

← 1 2 3 4 5 →